Catalyst

Slingshot members are tracking this event:

Tesaro (TSRO) expects Phase 2 data from QUADRA study of Niraparib in subjects with ovarian cancer in Q2 2016

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
TSRO

100%

Additional Information

Additional Relevant Details This is a Phase 2, open-label, single arm study to evaluate the safety and efficacy of niraparib in ovarian cancer patients who have received at least three previous chemotherapy regimens. Niraparib is an orally active PARP inhibitor.
https://clinicaltria...
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 29, 2016
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 2 Data, Parp Inhibitors, Niraparib, Ovarian Cancer